Swiss biotech ADC Therapeutics guns for $150M IPO

After a bumper series of private funding rounds, cancer biotech ADC Therapeutics is now looking to go public with a $150 million New York Stock Exchange IPO attempt.

Back in June, ADC expanded its series E by $76 million, bringing the financing to a massive $276 million and its total haul to $531 million. The cash, as well as its hoped for $150 million haul from its IPO, will advance the company’s pipeline of pyrrolobenzodiazepine-based antibody-drug conjugates (ADCs), including an FDA submission for its lead program in 2020.